One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies
induced by previous infection or vaccination through mutations in the spike protein …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

Small number of SARS-CoV-2 epidemic lineages did not efficiently exhibit a neutralization
profile, while single amino acid mutation in the spike protein has not been confirmed in …

The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies in the serum of an individual indicates previous infection or vaccination …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …